Smooth Drug Development October 2026 News Release
News – October 2026
Clinical and Scientific Departments News:
Phase I-IV Clinical Trials
• A Phase I Hodgkin Lymphoma Study: A total of 23 subjects have been screened, and 19 have been randomized.
• A Phase I Urothelial Cancer Study: Clinical Trial Authorization (CTA) has been obtained in Russia, and site selection visits have been conducted.
• A Phase II–III Morbid Obesity Study: The study documents have been submitted to the Ministry of Health of the Russian Federation.
• A Phase III Immunology Study: Approval has been obtained from the Ministry of Health and the Ethics Committee of Armenia, and site initiation is planned.
• A Phase III Dermatology Study: 6 sites have been opened. A total of 124 subjects have been screened, and 116 have been randomized.
• A Phase III Infectious Disease Study I: Patient recruitment and randomization have been completed, and the number of randomized patients exceeded the originally planned sample size.
• A Phase III Infectious Disease Study II: The independent audit in Tashkent was completed successfully.
• A Phase III Primary Immune Thrombocytopenia (ITP) Study: All patients have completed their participation in the study.
• A Phase III Gynecology Study: All patients have completed the study.
• A Phase III Breast Cancer Study I: A total of 48 patients have been screened, and 42 have been enrolled.
• A Phase III Breast Cancer Study II: 13 site selection visits have been conducted in Russia and Uzbekistan.
• A Phase IV Neurology (Spinal Muscular Atrophy) Study: All planned participants have been enrolled, and recruitment closed.
Bioequivalence (BE) Study
• A BE Study in Patients with Breast Cancer: 10 sites have been opened.
Business Development News:
Our Business Development team has been actively expanding partnerships and exploring new opportunities through strategic discussions and conference participation.
Key Partner Engagements
• The Smooth Drug Development Business Development team attended CPHI Milan 2026 from 6–8 October 2026 at Fiera Milano, Italy.
• The business development team of Smooth Drug Development attended World Vaccine Congress Europe 2026 from 19–21 October 2026 at the RAI Convention Centre, Amsterdam.